Short-Term Efficacy of Tislelizumab with Carboplatin/Cisplatin Pemetrexed in Advanced Lung Adenocarcinoma and its Effect on Tumor Markers

We attempt to study the short-term efficacy of tislelizumab+carboplatin/cisplatin+pemetrexed in advanced lung adenocarcinoma and its effect on tumor markers. Retrospectively analyzed the clinical data of 68 advanced lung adenocarcinoma patients admitted to our hospital from May 2019 to June 2021 and divided them into control group (n=34) and study group (n=34). Treated control group with carboplatin or cisplatin+pemetrexed, while treated study group with tislelizumab+carboplatin or cisplatin+pemetrexed. Compared both groups on total clinical response rate, serum tumor marker levels and immune function indexes before treatment and after 6 mo treatment. Study group had higher total effective rate than control group (p<0.05); after 6 mo treatment, study group had lower serum carbohydrate antigen 125, carbohydrate antigen 199 and carcinoembryonic antigen levels than control group (p<0.05). Meanwhile, study group had higher cluster of differentiation 3, cluster of differentiation 4 and cluster of differentiation 4/cluster of differentiation 8 than control group, while lower cluster of differentiation 8 than control group (p<0.05). Tislelizumab plus carboplatin or cisplatin plus pemetrexed therapy in advanced lung adenocarcinoma can improve short-term efficacy, reduce serum tumor marker levels and improve immune function.